

Table SII. Treatment-emergent adverse events (TEAEs) leading to withdrawal of investigational product by system organ class and preferred term in constant treatment groups from baseline until week 12, period 1 (safety analysis set)

| | Placebo <i>n</i> = 881; 200.2 PYE | | | Ustekinumab <i>n</i> = 612; 139.5 PYE | | | Brodalumab 140 mg Q2W <i>n</i> = 1,490; 342.3 PYE | | | Brodalumab 210 mg Q2W <i>n</i> = 1,495; 344.4 PYE | | |
|--|--------------------------------------|---|----------|--|---|----------|--|----|----------|--|----|----------|
| | <i>n</i> (%) | E | E/100 PY | <i>n</i> (%) | E | E/100 PY | <i>n</i> (%) | E | E/100 PY | <i>n</i> (%) | E | E/100 PY |
| All TEAEs leading to withdrawal | 4 (0.5) | 4 | 2.0 | 7 (1.1) | 7 | 5.0 | 16 (1.1) | 16 | 4.7 | 17 (1.1) | 22 | 6.4 |
| Investigations | 1 (0.1) | 1 | 0.5 | 2 (0.3) | 2 | 1.4 | 4 (0.3) | 4 | 1.2 | 1 (0.1) | 1 | 0.3 |
| Liver function test abnormal | 1 (0.1) | 1 | 0.5 | 1 (0.2) | 1 | 0.7 | 1 (0.1) | 1 | 0.3 | 0 | | |
| Electrocardiogram QT prolonged | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 | 0 | | |
| Eosinophil count increased | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 | 0 | | |
| Hepatic enzyme increased | 0 | | | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 |
| Neutrophil count abnormal | 0 | | | 1 (0.2) | 1 | 0.7 | 0 | | | 0 | | |
| Neutrophil count decreased | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 | 0 | | |
| Skin and subcutaneous tissue disorders | 0 | | | 0 | | | 3 (0.2) | 3 | 0.9 | 2 (0.1) | 3 | 0.9 |
| Psoriasis | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 | 1 (0.1) | 2 | 0.6 |
| Urticaria | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 | 0 | | |
| Eczema | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 | 0 | | |
| Erythrodermic psoriasis | 0 | | | 0 | | | 0 | | | 1 (0.1) | 2 | 0.3 |
| Gastrointestinal disorders | 0 | | | 0 | | | 2 (0.1) | 2 | 0.6 | 3 (0.2) | 3 | 0.9 |
| Colitis ulcerative | 0 | | | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 |
| Gastritis | 0 | | | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 |
| Gastroenteritis eosinophilic | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 | 0 | | |
| Pancreatitis acute | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 | 0 | | |
| Upper gastrointestinal haemorrhage | 0 | | | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 |
| Infections and infestations | 1 (0.1) | 1 | 0.5 | 0 | | | 0 | | | 4 (0.3) | 4 | 1.2 |
| Appendicitis | 0 | | | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 |
| Meningitis cryptococcal | 0 | | | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 |
| Oesophageal candidiasis | 0 | | | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 |
| Sinusitis | 1 (0.1) | 1 | 0.5 | 0 | | | 0 | | | 0 | | |
| Staphylococcal skin infection | 0 | | | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 |
| Musculoskeletal and connective tissue disorders | 0 | | | 0 | | | 3 (0.2) | 3 | 0.9 | 2 (0.1) | 2 | 0.6 |
| Arthralgia | 0 | | | 0 | | | 2 (0.1) | 2 | 0.6 | 1 (0.1) | 1 | 0.3 |
| Dactylitis | 0 | | | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 |
| Psoriatic arthropathy | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 | 0 | | |
| Blood and lymphatic system disorders | 1 (0.1) | 1 | 0.5 | 0 | | | 1 (0.1) | 1 | 0.3 | 2 (0.1) | 2 | 0.6 |
| Neutropaenia | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 | 2 (0.1) | 2 | 0.6 |
| Leukopaenia | 1 (0.1) | 1 | 0.5 | 0 | | | 0 | | | 0 | | |
| Cardiac disorders | 0 | | | 1 (0.2) | 1 | 0.7 | 3 (0.2) | 3 | 0.9 | 0 | | |
| Acute coronary syndrome | 0 | | | 1 (0.2) | 1 | 0.7 | 0 | | | 0 | | |
| Angina pectoris | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 | 0 | | |
| Arrhythmia | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 | 0 | | |
| Myocardial infarction | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 | 0 | | |
| General disorders and administration-site conditions | 1 (0.1) | 1 | 0.5 | 2 (0.3) | 2 | 1.4 | 0 | | | 1 (0.1) | 1 | 0.3 |
| Asthenia | 0 | | | 1 (0.2) | 1 | 0.7 | 0 | | | 0 | | |
| Fatigue | 0 | | | 1 (0.2) | 1 | 0.7 | 0 | | | 0 | | |
| Influenza-like illness | 0 | | | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 |
| Pain | 1 (0.1) | 1 | 0.5 | 0 | | | 0 | | | 0 | | |
| Neoplasms benign, malignant and unspecified (including cysts and polyps) | 0 | | | 1 (0.2) | 1 | 0.7 | 0 | | | 1 (0.1) | 1 | 0.3 |
| Bladder cancer | 0 | | | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 |
| Prostate cancer | 0 | | | 1 (0.2) | 1 | 0.7 | 0 | | | 0 | | |
| Nervous system disorders | 0 | | | 0 | | | 0 | | | 2 (0.1) | 2 | 0.6 |
| Cerebral infarction | 0 | | | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 |
| Subarachnoid haemorrhage | 0 | | | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 |
| Renal and urinary disorders | 0 | | | 0 | | | 0 | | | 2 (0.1) | 2 | 0.6 |
| Acute kidney injury | 0 | | | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 |
| Glomerulonephritis | 0 | | | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 |
| Hepatobiliary disorders | 0 | | | 1 (0.2) | 1 | 0.7 | 0 | | | 0 | | |
| Hepatic function abnormal | 0 | | | 1 (0.2) | 1 | 0.7 | 0 | | | 0 | | |
| Injury, poisoning and procedural complications | 0 | | | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 |
| Arthropod bite | 0 | | | 0 | | | 0 | | | 1 (0.1) | 1 | 0.3 |

E: number of events; E/100 PY: event rate per 100 patient-years; PYE: patient-years of exposure; Q2W: every 2 weeks.